{"groups":[{"description":"Patients will receive the following in every cycle (1 cycle=28days).\n\n* Paclitaxel - 175 mg/m2 over 3 hours via IV on Day 1\n* Carboplatin - AUC 6\\* (or AUC 5\\*) over 1 hour via IV on Day 1\n* Galunisertib - 150mg orally twice a day on Days 4-17","id":"FG000","title":"Paclitaxel/Carboplatin + Galunisertib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 26 enrolled participants, 24 met inclusion criteria (2 participants were screen-fails) and were assigned to the study arm to receive treatment. Of the 24 participants that received treatment, 23 participants were evaluable based on the protocol.","recruitmentDetails":"This single site study conducted at the University of Oklahoma Stephenson Cancer Center enrolled 26 participants between August 2017 and March 2021. The first participant was enrolled on August 23, 2017 and the last participant was enrolled on March 29, 2021."}